Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5810856 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL6366748 | 0.76 | ADORA2A (0.50) | MAOBADORA2AADORA2BADORA1MEN1 | |
| SCHEMBL5819628 | 0.74 | PKN1 (0.47) | PRKAG1PRKAA2PRKAB1LMNA | |
| SCHEMBL5822839 | 0.72 | KMT2A (0.51) | PRKAG1PRKAA2PRKAB1MEN1LMNA | |
| Trifluoroacetic Acid SCHEMBL6367442 | 0.71 | KMT2A (0.43) | PRKAG1PRKAA2PRKAB1MEN1LMNA | |
| SCHEMBL6363429 | 0.67 | MAOB (0.49) | MAOBADORA2AADORA2BADORA1MEN1 | |
| SCHEMBL6588786 | 0.64 | MEN1 (0.39) | PRKAG1PRKAA2PRKAB1MEN1LMNA | |
| SCHEMBL1437928 | 0.61 | KMT2A (0.80) | MEN1LMNAKMT2ANPC1MAPT | |
| SCHEMBL6362672 | 0.61 | ALDH1A1 (0.54) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL8474011 | 0.59 | JAK2 (0.56) | PARP1MEN1KMT2AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005511760-A | — | — | 2005-04-28 | — | — | JP | claimed |
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | claimed |
| EP-1458712-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051277-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458712-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051277-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | PARK7, HYPK, BCL2A1 | MAOB 2440/4885ADORA2A 3084/4885ADORA2B 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.